Anthony M. Rimac - 18 Jul 2023 Form 4 Insider Report for Sagimet Biosciences Inc. (SGMT)

Role
Chief Operating Officer
Signature
/s/ Dennis Hom, Attorney-in-Fact
Issuer symbol
SGMT
Transactions as of
18 Jul 2023
Net transactions value
$0
Form type
4
Filing time
20 Jul 2023, 16:18:20 UTC
Previous filing
13 Jul 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SGMT Stock Option (Right to Buy) Disposed to Issuer $0 -242,142 -100% $0.000000* 0 18 Jul 2023 Common Stock 242,142 $13.51 Direct F1, F2
transaction SGMT Stock Option (Right to Buy) Award $0 +242,142 $0.000000 242,142 18 Jul 2023 Series A Common Stock 242,142 $13.51 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock.
F2 25% of the shares underlying this option shall vest and become exercisable on April 10, 2024, with the remainder vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.